[1]hang Wei-Lin,Meng Hong-Zheng, Yang Rui-Fei, Yang Mao-Wei, Sun Guang-Hong, Liu Jun-Hua, et al.(2016). Melatonin suppresses autophagy in type 2 diabetic osteoporosis. Oncotarget, 7(32), 52179-52194. doi:10.18632/oncotarget.10538.
[2]Vestergaard P.(2007). Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos Int, 18(4), 427-44. doi:10.1007/s00198-006-0253-4.
[3]Räkel A, Sheehy O,Rahme E,LeLorier J,et al. Osteoporosis among patients with type 1 and type 2 diabetes.Diabetes & Metabolism,34(3), 193–205.doi:10.1016/j.diabet.2007.10.008.
[4]Inzucchi Silvio E,Bergenstal Richard M,Buse John B,Diamant Michaela,Ferrannini Ele,Nauck Michael et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Spectrum, 2012. 25(3): p. 154-171.doi:10.2337/diaspect.25.3.154.
[5]Zinman Bernard,Haffner Steven M,Herman William H,Holman Rury R,Lachin John M,Kravitz Barbara G,et al.Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. The Journal of Clinical Endocrinology & Metabolism, 2010. 95(1): p. 134-142.doi:10.1210/jc.2009-0572.
[6]Cortizo Ana M,Sedlinsky Claudia,McCarthy Antonio D,Blanco Alcira,Schurman León,et al. Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture.European journal of pharmacology, 2006. 536(1-2): p. 38-46.doi:10.1016/j.ejphar.2006.02.030
[7]Gao Ying,Li Yunfeng,Xue Jing,Jia Yongqian,Hu Jing.Effect of the anti-diabetic drug metformin on bone mass in ovariectomized rats. European journal of pharmacology, 2010. 635(1-3): p. 231-236.doi:10.1016/j.ejphar.2010.02.051.
[8]Lee Young-Sun,Kim Yang-Soon,Lee Sun-Young,Kim Geun-Hyang,Kim Beom-Jun,Lee Seung-Hun,et al.AMP kinase acts as a negative regulator of RANKL in the differentiation of osteoclasts. Bone, 47(5), 926–937. doi:10.1016/j.bone.2010.08.001.
[9]Mai Qi-guang,Zhang Zhong-min,Xu Song,Lu Ming,Zhou Rong-ping,Zhao Li,et al.Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. Journal of Cellular Biochemistry, 112(10), 2902–2909.doi:10.1002/jcb.23206.
[10]Kanazawa Ippei,Yamaguchi Toru,Yamamoto Masahiro,Sugimoto Toshitsugu.Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus. J Bone Miner Metab 28,554–560 (2010). doi:10.1007/s00774-010-0160-9.
[11]Gnanapragasam Arunachalam, Arun Prasath Lakshmanan, Samson Mathews Samuel,Chris R. Triggle,Hong Ding. Molecular Interplay between microRNA-34a and Sirtuin1 in Hyperglycemia-Mediated Impaired Angiogenesis in Endothelial Cells: Effects of Metformin. Journal of Pharmacology and Experimental Therapeutics, 2016. 356(2): p. 314-323.doi:10.1124/jpet.115.226894.
[12]Duarte Poliana Mendes,de Vasconcelos Gurgel, Bruno César,Sallum Antonio Wilson,Nogueira Filho Getúlio Rocha,Sallum Enilson Antonio,Nociti Jr Francisco Humberto.Alendronate therapy may be effective in the prevention of bone loss around titanium implants inserted in estrogen‐deficient rats. Journal of periodontology, 2005. 76(1): p. 107-114.doi:10.1902/jop.2005.76.1.107.
[13]Gong Xue,Yu Wanlu,Zhao Hang,Su Jiansheng,Sheng Qing.Skeletal Site-specific Effects of Zoledronate on in vivo Bone Remodeling and in vitro BMSCs Osteogenic Activity. Sci Rep 7, 36129 (2017). doi:10.1038/srep36129.
[14]Coe L M,Tekalur S A,Shu Y,Baumann M J, McCabe L R.Bisphosphonate treatment of type I diabetic mice prevents early bone loss but accentuates suppression of bone formation. J. Cell. Physiol, 2015. 230(8): p. 1944-1953. doi:10.1002/jcp.24929.
[15]Dong W, Qi M,Wang Y,Feng X, Liu H.Zoledronate and high glucose levels influence osteoclast differentiation and bone absorption via the AMPK pathway. Biochemical and biophysical research communications, 2018. 505(4): p. 1195-1202.doi.:10.1016/j.bbrc.2018.10.059.
[16]Chen T,Berenson J,Vescio R,Swift R,Gilchick A,Goodin S, et al.(2002), Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Bone Metastases. The Journal of Clinical Pharmacology, 42: 1228-1236. doi:10.1177/009127002762491316.
[17]Garris David R.(2004). Estrogenic stimulation of ovarian follicular maturation in diabetes (db/db) mutant mice: restoration of euglycemia prevents hyperlipidemic cytoatrophy. Cell Tissue Res., 318(2), 365-73. doi:10.1007/s00441-004-0967-6.
[18]Hosokawa T.Altered bone metabolism in db/db mice. Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, 1992. 29(7-8): p. 540-548.doi:10.3143/geriatrics.29.540.
[19]Williams G A,Callon K E,Watson M,Costa J L,Ding Y, Dickinson M.(2011),Skeletal phenotype of the leptin receptor–deficient db/db mouse. J Bone Miner Res, 26: 1698-1709. doi:10.1002/jbmr.367.
[20]Benayahu D,Shur I,Ben‐Eliyahu S. (2000), Hormonal changes affect the bone and bone marrow cells in a rat model. J. Cell. Biochem., 79: 407-415. doi:10.1002/1097-4644(20001201)79:3<407::AID-JCB60>3.0.CO;2-8.
[21]Gao Y,Xue J,Li X,Jia Y,Hu J.(2008),Metformin regulates osteoblast and adipocyte differentiation of rat mesenchymal stem cells. Journal of Pharmacy and Pharmacology, 60: 1695-1700. doi:10.1211/jpp.60.12.0017.
[22]John M Lachin, Costas A Christophi, Sharon L Edelstein, David A Ehrmann,Richard F Hamman, Steven E Kahn, et al.Factors Associated With Diabetes Onset During Metformin Versus Placebo Therapy in the Diabetes Prevention Program.Diabetes Apr 2007, 56 (4) 1153-1159; DOI: 10.2337/db06-0918.
[23]Malin Steven K,Kashyap Sangeeta R.(2014).Effects of metformin on weight loss: potential mechanisms.Curr Opin Endocrinol Diabetes Obes, 21(5), 323-9. doi:10.1097/MED.0000000000000095.
[24]Viollet Benoit,Guigas Bruno,Sanz Garcia Nieves,Leclerc Jocelyne,Foretz Marc, Andreelli Fabrizio.(2012). Cellular and molecular mechanisms of metformin: an overview. Clin. Sci., 122(6), 253-70. doi:10.1042/CS20110386.
[25]Rathinavelu Selvalakshmi,Guidry-Elizondo Crissy,Banu Jameela.(2018). Molecular Modulation of Osteoblasts and Osteoclasts in Type 2 Diabetes. J Diabetes Res, 2018(undefined), 6354787. doi:10.1155/2018/6354787.
[26]Cai Zhen-Yu,Yang Bo,Shi Ying-Xu,Zhang Wei-Lin,Liu Fei,Zhao Wei,et al.(2018).High glucose downregulates the effects of autophagy on osteoclastogenesis via the AMPK/mTOR/ULK1 pathway. Biochem. Biophys. Res. Commun., 503(2), 428-435. doi:10.1016/j.bbrc.2018.04.052.
[27]Zhang Fan,Xiang Hao,Fan Yunzhou,Ganchuluun Tsend-Ayush,Kong Wenhua, Ouyang Qian, et al.(2013).The effects of sulfonylureas plus metformin on lipids, blood pressure, and adverse events in type 2 diabetes: a meta-analysis of randomized controlled trials. Endocrine, 44(3), 648-58. doi:10.1007/s12020-013-9970-6.
[28]Morley Lara C,Tang Thomas,Yasmin Ephia,Norman Robert J,Balen Adam H.(2017).Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev, 11(undefined), CD003053. doi:10.1002/14651858.CD003053.pub6.
[29]Spinetti Gaia,Cordella Daniela,Fortunato Orazio,Sangalli Elena,Losa Sergio, Gotti Ambra, et al.(2013).Global remodeling of the vascular stem cell niche in bone marrow of diabetic patients: implication of the microRNA-155/FOXO3a signaling pathway. Circ. Res., 112(3), 510-22. doi:10.1161/CIRCRESAHA.112.300598.
[30]Isoda Kikuo,Young James L,Zirlik Andreas,MacFarlane Lindsey A,Tsuboi Naotake,Gerdes Norbert,et al.(2006).Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler. Thromb. Vasc. Biol., 26(3), 611-7. doi:10.1161/01.ATV.0000201938.78044.75.